Monday, August 31, 2026

Tilray Stock Bearish Momentum With A 20% Slide So Far On Friday

Tilray Stock Bearish Momentum With A 20% Slide So Far On Friday

(VIANEWS) - Shares of Tilray (NASDAQ: TLRY) dropped by a staggering 20.55% to $1.88 at 11:28 EST on Friday, after three successive sessions in a row of losses. NASDAQ is jumping 1.65% to $12,908.04, following the last session's upward trend. This seems, up until now, an all-around up trend exchanging session today.

Tilray's last close was $2.36, 54.35% under its 52-week high of $5.17.

About Tilray

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.

Earnings Per Share

As for profitability, Tilray has a trailing twelve months EPS of $-2.99.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -44.15%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 4.1%, now sitting on 596.26M for the twelve trailing months.

Moving Average

Tilray's worth is way below its 50-day moving average of $2.50 and way below its 200-day moving average of $3.16.

Previous days news about Tilray (TLRY)

  • : tilray stock drops following announced secondary offering. According to MarketWatch on Thursday, 25 May, "At the close, Tilray shares were down 12.2% year to date, compared with an 8.1% gain on the S&P 500 index ."

More news about Tilray (TLRY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com